Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
Milton, GB
Atopix was founded in 2012 and is headquartered in Milton, GB

Atopix Office Locations

Atopix has office in Milton
Milton, GB

Atopix Metrics

Atopix Summary

Founding Date


Total Funding

$5.1 m

Latest funding size

$5.1 m

Time since last funding

over 1 year


We estimate that Atopix's latest funding round in July 2015 was $5.1 m. In total, Atopix has raised $5.1 m

Atopix Financials

We estimate that Atopix's revenue is £316 k in FY, 2015 which is a 49.6% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


£225.3 k£626.7 k£316 k

Revenue growth, %


Atopix Company Life

You may also be interested in